Opinion|Videos|July 11, 2023
Beyond Glucose Control - The Expanding Role of Incretins in Diabetes and Obesity Management
In this MEDcast episode, Diana Isaacs, PharmD, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, interview Dr Juan Frias to explore the mechanism of GLP-1 and GIP agonists in diabetes and weight management and examine key findings from clinical trials for the latest GLP-1/GIP dual agonist.
Advertisement
1:00 Effect of incretins on blood glucose and body weight
3:24 Evolution of GLP-1 agonists
7:45 Mechanism of tirzepatide- dual GLP-1/GIP agonist
10:35 Overview of SURPASS and SURMOUNT trials for tirzepatide
17:45 Benefits vs. risks of GLP-1 agonists
21:45 Sustainability of weight loss with incretin-based therapies
25:30 Future of metabolic diseases management
Advertisement
Related to this article
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.
The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.
Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, unpack tirzepatide's new CV indication and the STAREE statin trial in older adults.
Advertisement
Advertisement
Trending on HCPLive
1
ASH Issues New Ferritin Thresholds for Iron Deficiency Diagnosis
2
Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD
3
FDA Approves Finerenone (Kerendia) for CKD and Type 1 Diabetes
4
Dersimelagon Gains FDA Priority Review for EPP, XLP
5